Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry-Reference-Cited by-同舟云学术

Liver microphysiological systems development guidelines for safety risk assessment in the pharmaceutical industry

Published:2020 Issue:2 Volume:20 Page:215-225
ISSN:1473-0197
Container-title:Lab on a Chip
language:en
Short-container-title:Lab Chip

Author:

Baudy Andreas R.¹²³^ORCID,Otieno Monicah A.⁴⁵³,Hewitt Philip⁶⁷⁸,Gan Jinping⁹¹⁰³^ORCID,Roth Adrian¹¹¹²¹³,Keller Douglas¹⁴³^ORCID,Sura Radhakrishna¹⁵¹⁶³,Van Vleet Terry R.¹⁵¹⁶³,Proctor William R.¹⁷¹⁸³

Affiliation:

1. Merck & Co., Inc.

2. Kenilworth

3. USA

4. Janssen Pharmaceutical Research and Development

5. Spring House

6. Merck KGaA

7. Darmstadt

8. Germany

9. Bristol-Myers Squibb

10. New York City

11. Roche Innovation Centre

12. Basel

13. Switzerland

14. Sanofi, Bridgewater

15. AbbVie, Inc.

16. Chicago

17. Genentech, Inc.

18. South San Francisco

Abstract

This pharmaceutical industry guidance based on a 3-staged benchmarking strategy aims to help MPS developers and end users identify what could be the most valuable models for safety risk assessment, as well as provide an overview of contexts of use.

Publisher

Royal Society of Chemistry (RSC)

Subject

Biomedical Engineering,General Chemistry,Biochemistry,Bioengineering

Link

http://pubs.rsc.org/en/content/articlepdf/2020/LC/C9LC00768G

Reference105 articles.

1. Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how

2. Drug-Induced Liver Injury Network (DILIN) Prospective Study

3. Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States

4. Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database

5. Concordance of the Toxicity of Pharmaceuticals in Humans and in Animals

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanobiological stimulation in organ‐on‐a‐chip systems reduces hepatic drug metabolic capacity in favor of regenerative specialization;Biotechnology and Bioengineering;2024-01-07

2. State of the Art in Integrated Biosensors for Organ-on-a-Chip Applications;Functional Smart Nanomaterials and Their Theranostics Approaches;2024

3. Towards in vitro models for reducing or replacing the use of animals in drug testing;Nature Biomedical Engineering;2023-12-27

4. Patient‐Derived Microphysiological Systems for Precision Medicine;Advanced Healthcare Materials;2023-12-10

5. Rapid Prototyping of Thermoplastic Microfluidic 3D Cell Culture Devices by Creating Regional Hydrophilicity Discrepancy;Advanced Science;2023-11-30